Understanding how genetic background affects rare tumors and their treatment responses
Official title: Evaluating the impact of genetic ancestry on the biology and drug response profile of pheochromocytoma and paraganglioma-derived organoid models
Funded at University of Texas Hlth Science Center · NIH-10922102 · Data updated 2026-11-12
This study is looking at how your genetic background might affect the way rare tumors called pheochromocytomas and paragangliomas behave and respond to treatment, especially for patients from underrepresented racial and ethnic groups, to help find better ways to detect and treat these tumors.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | University of Texas Hlth Science Center NIH-funded |
| Lab location | 1 site (San Antonio, United States) |
| Project start | September 8, 2021 |
| Project end | August 31, 2026 |
| Funding year | 2024 |
| Award (this year) | $265,946 |
| NIH project number | 3R01CA264248-04S2 |
| Project ID | NIH-10922102 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates for this research include individuals from underrepresented racial and ethnic backgrounds diagnosed with pheochromocytomas or paragangliomas.
✕Less likely to help
Patients with common tumors or those not from the targeted racial and ethnic groups may not benefit from this research.
What this research studies
This research investigates the role of genetic ancestry in the biology and treatment responses of rare neuroendocrine tumors called pheochromocytomas and paragangliomas. By creating patient-derived organoid models, the study aims to identify how genetic factors and social determinants influence tumor behavior and drug effectiveness. The research focuses on underrepresented racial and ethnic minority patients, aiming to improve early detection and treatment options for aggressive forms of these tumors. Patients will be recruited to provide samples that will help develop these innovative models.
Why it matters
Potential benefit: If successful, this research could lead to more personalized and effective treatment strategies for patients with rare tumors.
How similar studies have gone: Previous research has shown promise in using patient-derived organoid models to study cancer, indicating potential for success in this novel approach.
Where this research is happening
-
University of Texas Hlth Science Center
San Antonio, United States Active
Researchers
- Principal investigator: Dahia, Patricia Leal — University of Texas Hlth Science Center
- Study coordinator: Dahia, Patricia Leal
Related research
Other NIH-funded projects on the same topics.
-
Understanding genetic factors in hereditary paraganglioma and pheochromocytoma syndrome
This study is looking at how certain genes might affect the chances of developing adrenal tumors called paragangliomas and pheochromocytomas, so if you or someone you know is at risk, this research could help improve testing and treatment options for you.
-
Identifying weaknesses in a type of cancer linked to genetic mutations.
This study is looking at a type of inherited cancer called familial paraganglioma to find out how certain genetic weaknesses in cancer cells can help us develop new treatments that specifically target those weaknesses.
-
NET- and somatostatin-targeted PET/SPECT imaging to find and stage neuroblastoma and pheochromocytoma/paraganglioma
This study will try different PET and SPECT tracers to see if they can accurately find and stage tumors in children and adults with neuroblastoma or pheochromocytoma/paraganglioma.
-
Combining Lutathera® and Olaparib for treating recurrent solid tumors in children and adolescents
This study is testing if combining Lutathera® with olaparib can help children and teenagers with hard-to-treat solid tumors that have certain receptors.
-
Registry for Rare Diseases
This study is creating a detailed registry to collect information on rare diseases like amyloidosis and sarcoidosis to help improve how they are diagnosed and treated.
-
Understanding genetic causes of neuroendocrine tumors in Mexican patients
This study is trying to find out the genetic changes that cause neuroendocrine tumors in Mexican patients to help develop better treatments.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.